<DOC>
	<DOCNO>NCT01227694</DOCNO>
	<brief_summary>This prospective , open-label , single-dose , single-arm phase I-II study 15 patient diagnosed gonarthrosis grade II-III ( Kellgren Lawrence ) enter study primary objective assess feasibility safety knee articular infiltration autologous bone marrow mesenchymal stem cell ( MSC ) . Secondary objective assess efficacy image procedure clinical questionnaire . MSC obtain patient 's bone marrow isolate expanded `` Ex-Vivo '' GMP condition Xcelia-Divisi√≥n de Terapias avanzadas del Banc de Sang I Teixits . After 21 day , patient implant single-dose approximately 40 million autologous MSC knee articular injection , follow 12 month . Articular cartilage change determine T2-weighted MRI ( Cartigram ) 6 12 month . Clinical assessment measure pain visual analogue scale ( VAS ) , self-reported functional status Heath Assessment Questionnaire ( HAQ ) , quality life Short Form 36 questionnaire ( SF-36 ) 3 , 6 12 month . The work hypothesis proposes expect regenerative articular cartilage effect MSC produce measurable degree imaging procedure clinical questionnaire .</brief_summary>
	<brief_title>Adult Stem Cell Therapy Repairing Articular Cartilage Gonarthrosis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Knee Injuries</mesh_term>
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Cartilage Diseases</mesh_term>
	<criteria>1 . Gonarthrosis grade IIIII Kellgren Lawrence assess two observer 2 . Chronic knee pain mechanical characteristic 3 . Absence local systemic septic process 4 . Haematological biochemical laboratory test without significant alteration contraindicate treatment . 5 . Informed Consent form sign patient 6 . The patient able understand nature study 1 . Patients &lt; 18 year legally dependent 2 . Patients &gt; 65 year 3 . Previous surgery knee 4 . Intraarticular treatment past 6 month 5 . Knee ligament meniscus rupture observe MRI 6 . Any sign infection 7 . Positive serology HIV1 HIV2 , Hepatitis B ( HBsAg ) , Hepatitis C ( AntiHCVAb ) syphilis . 8 . Congenital acquire malformation result significant deformity knee lead problem application evaluation result . 9 . Overweight express body mass index ( BMI ) great 30.5 ( obesity grade II ) . BMI estimate mass ( kg ) / corporal surface ( m2 ) . 10 . Pregnant woman intend become pregnant breastfeed 11 . Neoplasia 12 . Immunosuppressive state 13 . Participation another clinical trial treatment different investigational product within 30 day prior inclusion study . 14 . Other pathologic condition circumstance difficult participation study accord medical criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Cell therapy</keyword>
	<keyword>Regenerative therapy</keyword>
	<keyword>Advance therapy</keyword>
	<keyword>Bone marrow</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Autologous</keyword>
	<keyword>Interventional clinical trial</keyword>
	<keyword>Osteoarthrosis</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>Knee</keyword>
</DOC>